China Pharma Holdings, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 15, 2024. China Pharma is a Nevada holding company whose wholly owned operating subsidiary, Helpson, develops, manufactures, and sells pharmaceutical products in China.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $1.370 million | $1.960 million; down 30.1% |
| Gross profit (loss) and margin | $(290,024); (21.2%) | $177,924; 9.1% |
| Operating loss | $(916,052) | $(397,479) |
| Net loss | $(955,892) | $(475,976) |
| Net loss per share | $(0.07) | $(0.29) |
| Cash used in operating activities | $(585,158) | $(1,468,214) |
Cost of revenue was $1.660 million, or 121.2% of revenue, versus 90.9% a year earlier. Management attributed the higher cost ratio mainly to fixed costs remaining relatively flat as revenue fell. Operating expenses totaled $626,028, including $488,456 of general and administrative expense and $31,451 of R&D expense. Net interest expense was $39,840.
At March 31, cash and cash equivalents were $838,881, down from $1.424 million at year-end 2023. Current assets were $5.124 million and current liabilities $5.728 million, a working-capital deficit of approximately $604,000. Total liabilities were $7.898 million. Debt included $2.438 million of lines of credit, $1.139 million owed to the CEO/Chairperson, and a $490,000 net convertible note payable. The CEO-related loan is due July 9, 2024; bank facilities include amounts due in December 2024 and February 2025, and a facility due in 2026. The company reported no investing cash flow in Q1 2024 and $6,856 of financing cash flow.
Net trade receivables were $358,765, against gross receivables of $14.119 million and an allowance of $13.760 million. Approximately 97.4% of gross receivables were over 720 days old. Inventories were $3.679 million. The company says its $838,881 of cash is held in its PRC subsidiary and is not expected to be available for dividends or other payments to the parent or shareholders.
Material changes and notable transactions
- Revenue declined across all reported product categories. Management cited lower selling prices following certain products’ inclusion in centralized drug procurement, as well as market volatility affecting Vitamin B6 for Injection, Omeprazole, Candesartan, and Andrographolide.
- Anti-Viral/Infection & Respiratory products accounted for 54.4% of revenue; two products together accounted for 64.8% of revenue. Three suppliers represented 77% of raw-material purchases, and two customers represented 76.8% of accounts receivable.
- In February, Helpson acquired a psoriasis-treatment patent and related technical services for $1.365 million, paid through issuance of 3,000,000 common shares. The asset is to be amortized over approximately 20 years; if the product launches and generates profit, the transferor is entitled to 10% of net sales profit for ten years.
- During Q1, $450,000 of convertible-note balance was redeemed through share issuances. The company implemented a 1-for-5 reverse stock split on March 6, 2024; share and per-share figures are stated as retrospectively adjusted in the filing. Shares outstanding were 14,816,865 at March 31 and 15,870,070 as of May 14.
- After quarter-end, the note investor redeemed a further $300,000 of principal and related interest, receiving 1,053,205 shares in April. The note’s conversion price is based on 82% of the lowest volume-weighted average price over a specified ten-trading-day period, creating potential dilution.
Outlook, risks, and controls
The filing reports substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. The company had $0.8 million in cash, a $40.2 million accumulated deficit, ongoing losses, and dependence on CEO advances and financing. Management plans to improve advance-payment sales and collections, pursue strategic alternatives to accelerate nutrition-product launches, and consider using property and equipment as collateral for additional bank loans. However, management states these plans are not finalized or sufficiently probable to alleviate substantial doubt; there is no assurance of additional financing or continued CEO support.
Management expects operating losses to continue for the foreseeable future. It cites changes in China’s centralized procurement and generic-drug consistency-evaluation policies, which can affect market access and pricing. Substantially all operations and revenue are in China and denominated in RMB; PRC rules may restrict currency conversion and remittances. The filing also notes that two customers account for a substantial share of receivables and that most gross receivables are more than two years old.
The company’s disclosure controls were deemed ineffective at March 31, 2024 because of a material weakness: insufficient accounting and financial-reporting personnel knowledgeable in U.S. GAAP. Management nevertheless concluded the interim financial statements were fairly stated in all material respects. No off-balance-sheet arrangements were reported. No specific financial guidance was provided.
Investor verification points
- Whether the company can fund operations, refinance or repay near-term obligations, and obtain financing despite the stated going-concern doubt.
- Actual collections on the heavily aged receivables, the adequacy of the allowance, and the availability of cash held in China to support the parent company.
- Further convertible-note redemptions, resulting share issuance and dilution, and the note’s remaining balance and maturity status.
- Whether lower product prices and sales volumes improve enough to restore positive gross margins, and whether the new patent products progress toward regulatory approval and commercial launch.
- Plans and progress to remediate the material weakness in U.S. GAAP reporting controls.